Oppenheimer Starts Protera Therapeutics (TARA) at Outperform

Oppenheimer analyst Leland Gershell initiates coverage on Protera Therapeutics (NASDAQ: TARA) with a Outperform rating and a price target of $43.00.

The analyst comments "We initiate coverage of Protara (TARA) with an Outperform rating and a $43 price target. TARA is currently advancing two therapeutic candidates, each of which offers transformative potential for their respective indications while bearing solid validation. TARA-002 will begin clinical development for non–muscle invasive bladder cancer this year, but may well reach the market first for lymphatic malformations, an ultra-rare pediatric condition that needs better options. IV choline chloride is positioned to reverse the liver disease that frequently afflicts those who receive parenteral nutrition over time. Leadership is committed to strategic portfolio growth through creative exploration, and cash resources are ample following last fall's ~$150M equity financing."

For an analyst ratings summary and ratings history on Protera Therapeutics click here. For more ratings news on Protera Therapeutics click here.

Shares of Protera Therapeutics closed at $20.88 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery